Edwards received notification from a field clinical specialist that a patient underwent transfemoral tavr with a 26mm s3ur.As reported, the delivery system balloon ruptured upon full inflation and once the valve was fully deployed.There was moderate degree of calcium in the landing zone.No extra volume was added to the balloon prior to the inflation.The balloon/delivery system was able to be removed in normal fashion.The patient was stable, and the team felt the valve was fully expanded so there was no need to post dilate.The device was discarded.
|
The event reported is an anticipated in the risk management documentation for transcatheter heart valve procedures.A previous investigation into this type of event is captured in an edwards lifesciences technical summary and applies to this complaint.Additional assessment of the failure mode is not required at this time.Due to the unavailability of the complaint device, engineering was unable to perform any visual inspection, functional testing, or dimensional analysis.Per the technical summary, the ifu, current risk mitigations include design and manufacturing controls, and training manuals have been reviewed , no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.In this case, the balloon burst was confirmed based on the evaluation of the provided imagery.Available information suggests patient factors (calcification ) likely contributed to the event as the event description stated, ''there was moderate degree of calcium in the landing zone''.The presence of calcification can create a challenging anatomy for balloon inflation.While the balloons are sufficiently designed and tested to ensure the burst pressure is at or above the rated burst pressure, calcified nodules can compromise the structure of the balloon wall via following mechanisms such as puncture, local overstretching, open cell impingement, or stress concentration.Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review.Since no edwards product defects or labeling deficiencies were identified, no corrective or preventative action is required.
|